Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call...
Day: July 2, 2026
Lanas appoints Rob Hutcheson as Chief Corporate Development Officer to accelerate acquisition strategy
DUBLIN, July 2, 2026 /PRNewswire/ -- Irish-headquartered healthcare technology business, Lanas, has appointed Rob Hutcheson as Chief Corporate Development Officer,...
Lanas appoints Rob Hutcheson as Chief Corporate Development Officer to accelerate acquisition strategy
DUBLIN, July 2, 2026 /PRNewswire/ -- Irish-headquartered healthcare technology business, Lanas, has appointed Rob Hutcheson as Chief Corporate Development Officer,...
Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System
~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of...
Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System
~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of...
Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY
Vancouver, British Columbia--(Newsfile Corp. - July 2, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Black Book Italy Provider Pulse Finds FSE 2.0 Faces Regional Interoperability, Diagnostic-Data and EHDS Readiness Test
Survey of Italian healthcare IT users finds regional fragmentation, diagnostic-data usability and PNRR deadline pressure are redefining Italy's EHR/HIT competitive...
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in ChinaHONG KONG and...
Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer
BASEL, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune...
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical...
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a...
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world...
DXS INTERNATIONAL PLC (AQSE: DXSP): Trading Update
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU)...
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS,...
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed...
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company...
FDA Alignment to Advance ProstACT Global Phase 3 Trial
FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA...
GNI Group Completes Acquisition of AYUMI Pharmaceutical
Japan-Originated Global Biopharma Company Founded in 2001 Enters Its “Second Founding Phase”TOKYO, July 01, 2026 (GLOBE NEWSWIRE) -- GNI Group...
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...